[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-329894-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-329894-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-pathologic-and-clinical-outcomes-of-risk-reducing-salpingo-oophorectomy-in-asymptomatic-carriers-of-homologous-recombination-repair-gene-mutation","The pathologic and clinical outcomes of risk-reducing salpingo-oophorectomy in asymptomatic carriers of homologous recombination repair gene mutation","","Objective: investigate the prevalence of pathological findings and clinical outcomes of risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic carriers with germline homologous recombination repair (HRR) gene pathogenic/likely pathogenic variants. Methods: retrospective analysis of asymptomatic carriers with germline HRR PV/LPV undergoing RRSO between 2006 and 2022 at the National Cancer Center in Korea, assessing clinical characteristics and follow-up outcomes. Results: among 255 women, occult neoplasms were found in 3.5%, and one BRCA1 PV carrier without precursor lesions developed primary peritoneal carcinomatosis after 30.1 months during median follow-up of 36.7 months. Conclusion: RRSO carries risk of occult neoplasms and cumulative peritoneal carcinomatosis, supporting continued surveillance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-pathologic-and-clinical-outcomes-of-risk-reducing-salpingo-oophorectomy-in-asymptomatic-carriers-of-homologous-recombination-repair-gene-mutation/329894/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-pathologic-and-clinical-outcomes-of-risk-reducing-salpingo-oophorectomy-in-asymptomatic-carriers-of-homologous-recombination-repair-gene-mutation/329894.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of this study?","Question",{"text":63,"@type":64},"To investigate how often pathological findings occur and what clinical outcomes follow risk-reducing salpingo-oophorectomy in asymptomatic carriers of germline HRR gene PV/LPV.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study conducted and who was included?",{"text":68,"@type":64},"A retrospective study enrolled asymptomatic carriers with germline HRR gene PV/LPV who underwent RRSO from 2006 to 2022 at the National Cancer Center in Korea.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding occult neoplasms and later disease?",{"text":72,"@type":64},"Occult neoplasms were identified in 3.5% of patients among BRCA1/2 PV/LPV carriers, and one BRCA1 PV carrier without precursor lesions developed primary peritoneal carcinomatosis after 30.1 months.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},329894,1790135059,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","J Gynecol Oncol. 2025 Mar;36(2):e15 [https://doi.org/10.3802/jgo.2025.36.e15](https://doi.org/10.3802/jgo.2025.36.e15)[ ](https://doi.org/10.3802/jgo.2025.36.e15)pISSN 2005-0380·eISSN 2005-0399  \nOriginal Article  \nReceived: Jan 29, 2024  \nRevised: May 16, 2024  \nAccepted: Jun 25, 2024  \nPublished online: Jul 5, 2024  \nCorrespondence to  \nMyong Cheol Lim  \nRare and Pediatric Cancer Branch and Immuno-Oncology Branch, Division of Rare and Refractory Cancer, Research Institute and Center for Clinical Trial, Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea.  \n[Email: mclim@ncc.re.kr](Email: mclim@ncc.re.kr)  \n*Yeon Jee Lee and Ji Hyun Kim contributed equally to this work as first authors.  \n© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nYeon Jee Lee  [https://orcid.org/0000-0002-6652-5139](https://orcid.org/0000-0002-6652-5139)[ ](https://orcid.org/0000-0002-6652-5139)Ji Hyun Kim  [https://orcid.org/0000-0002-4746-5572](https://orcid.org/0000-0002-4746-5572)[ ](https://orcid.org/0000-0002-4746-5572)Youn Jee Kim  [https://orcid.org/0009-0007-4063-3207](https://orcid.org/0009-0007-4063-3207)[ ](https://orcid.org/0009-0007-4063-3207)Yoon Jung Chang  [https://orcid.org/0000-0001-7750-4213](https://orcid.org/0000-0001-7750-4213)[ ](https://orcid.org/0000-0001-7750-4213)[Sun-Young Kong](Sun-Young Kong)  [https://orcid.org/0000-0003-0620-4058](https://orcid.org/0000-0003-0620-4058)  \nThe pathologic and clinical outcomes of risk-reducing salpingo-oophorectomy inasymptomatic carriers of homologous recombination repair gene mutation  \nYeon Jee Lee ,1,2,* Ji Hyun Kim ,1,* Youn Jee Kim ,3 Yoon Jung Chang ,4 Sun-Young Kong ,5 Chong Woo Yoo ,6 Dong Ock Lee ,1 Sang-Soo Seo ,1 Sokbom Kang ,1 Sang-Yoon Park ,1 Myong Cheol Lim  1,7,8  \n1Center for Gynecologic Cancer, Hospital, National Cancer Center, Goyang, Korea  \n2Department of Obstetrics and Gynecology, Myongji Hospital, Goyang, Korea  \n3Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea 4Department of Family Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Korea 5Department of Laboratory Medicine and Genetic Counseling Clinic, Hospital, National Cancer Center, Goyang, Korea  \n6Center for Gynecologic Cancer and Department of Pathology, Research Institute and Hospital, National Cancer Center, Goyang, Korea  \n7Rare and Pediatric Cancer Branch and Immuno-Oncology Branch, Division of Rare and Refractory Cancer, Research Institute and Center for Clinical Trial, Hospital, National Cancer Center, Goyang, Korea 8Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea  \nABSTRACT  \nObjective: To investigate the prevalence of pathological findings and clinical outcomes of riskreducing salpingo-oophorectomy (RRSO) in asymptomatic carriers with germline homologous recombination repair (HRR) gene pathogenic/likely pathogenic variants (PV/LPV) .  \nMethods: This retrospective study enrolled asymptomatic carriers with germline HR gene PV/ LPV who underwent RRSO between 2006 and 2022 at the National Cancer Center in Korea. Clinical characteristics, including history of breast cancer, family history of ovarian/breast cancer, parity, and oral contraceptive use, were analyzed.  \nResults: Of the 255 women who underwent RRSO, 129 (50.6%) had PV/LPVin BRCA1, 121 (47.5%) in BRCA2, and 2 (0.7%) had both BRCA1 and BRCA2 PV/LPV. In addition, 1 carried PV/ LPV in RAD51D, and 2 in BRIP","cbCaiv40vkO7A8sy","https://ap.wps.com/l/cbCaiv40vkO7A8sy","pdf",4798590,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusion\n## Keywords","[{\"question\":\"What was the main objective of this study?\",\"answer\":\"To investigate how often pathological findings occur and what clinical outcomes follow risk-reducing salpingo-oophorectomy in asymptomatic carriers of germline HRR gene PV/LPV.\"},{\"question\":\"How was the study conducted and who was included?\",\"answer\":\"A retrospective study enrolled asymptomatic carriers with germline HRR gene PV/LPV who underwent RRSO from 2006 to 2022 at the National Cancer Center in Korea.\"},{\"question\":\"What were the key findings regarding occult neoplasms and later disease?\",\"answer\":\"Occult neoplasms were identified in 3.5% of patients among BRCA1/2 PV/LPV carriers, and one BRCA1 PV carrier without precursor lesions developed primary peritoneal carcinomatosis after 30.1 months.\"}]","The pathologic and clinical outcomes of risk-reducing salpingo-oophorectomy in asymptomatic carriers of homologous recombination repair gene mutation | PDF",1789986054,25]